Imeglimin
![]() | |
| Names | |
|---|---|
| IUPAC name
(2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine | |
| Identifiers | |
| 775351-65-0 | |
| 3D model (Jmol) | Interactive image |
| ChemSpider | 26232690 |
| |
| |
| Properties | |
| C6H13N5 | |
| Molar mass | 155.21 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Imeglimin is an experimental drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.
References
This article is issued from Wikipedia - version of the 8/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
